TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04641455
Drug: Water
Normalized name: Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of water before upper endoscopy
Study: NCT03109379
Drug: Trospium-Releasing Intravesical System (TAR-302-5018)
Normalized name: trospium Extended Release Oral Capsule
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Study: NCT02108860
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
Study: NCT02047539
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg/day of aspirin 1000 mg/day of sugar pill
Study: NCT00587470
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum vasodilation.
Study: NCT00587470
Drug: atacand
Normalized name: Atacand
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maximum vasodilation
Study: NCT01387737
Drug: TA-7284-Low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TA-7284-Low
Study: NCT01387737
Drug: TA-7284-High
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-7284-High
Study: NCT00138515
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00397241
Drug: Drug: dorzolamide/timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01167725
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01167725
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intraperitoneally
Study: NCT01167725
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00397241
Drug: Drug: latanoprost/timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00397241
Drug: dorzolamide/timolol and latanoprost
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03120273
Drug: Dexlansoprazole Injection
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
Study: NCT03120273
Drug: Lansoprazole Injection
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg q12h for 5 days.
Study: NCT03292653
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT00911898
Drug: MM-111
Normalized name: MM-111
DrugBank: MM-111 (DB17983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
Study: NCT02278887
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient receives 5 days fludarabine via IV to deplete T-cells.
Study: NCT02278887
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
Study: NCT02278887
Drug: Ipilimumab infusion
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In arm A patients will be treated with 4 infusion of ipilimumab
Study: NCT04507711
Drug: 0 ul of palonosetron
Normalized name: palonosetron 0.25 MG
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
Study: NCT04507711
Drug: 1 ul of palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
Study: NCT04507711
Drug: 10 ul of palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
Study: NCT04507711
Drug: 100 ul of palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
Study: NCT00003528
Drug: raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03798626
Drug: Gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL concentration; administered intravenously (IV)
Study: NCT03798626
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/mL concentration; administered IV
Study: NCT03798626
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/mL concentration; administered IV
Study: NCT03798626
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/mL concentration; administered IV
Study: NCT03798626
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg tablet; administered orally
Study: NCT01194453
Drug: cisplatin, gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
Study: NCT02894710
Drug: Lidocaine 20mg/ml
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
Study: NCT01999569
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole administered daily through the time of ovulation.
Study: NCT00423761
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02215161
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03409848
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
Study: NCT03409848
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
Study: NCT03409848
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
Study: NCT01876251
Drug: PF-03084014
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 10 mg, twice a day
Study: NCT01876251
Drug: PF-03084014
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 50 mg, twice a day
Study: NCT01876251
Drug: PF-03084014
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 100 mg, twice a day
Study: NCT01876251
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for IV infusion 75 mg/m\^2, every 3 weeks
Study: NCT01876251
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for IV infusion 100 mg/m\^2, every 3 weeks
Study: NCT00399789
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine will be tested in 3 dose forms
Study: NCT03335163
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily
Study: NCT00525044
Drug: Ambroxol
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234468
Drug: Iressa (Gefitinib)
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00208975
Drug: Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial patients (n=9) received fludarabine (25 mg/m\^2 intravenously) and mitoxantrone (10 mg/m\^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m\^2 intravenously) and cyclophosphamide (250 mg/m\^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management.
Study: NCT02220842
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
Study: NCT02220842
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
Study: NCT02220842
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
Study: NCT00959036
Drug: ATN-103
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg every 4 weeks until week 12
Study: NCT00959036
Drug: ATN-103
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg every 8 weeks until week 12
Study: NCT00959036
Drug: ATN-103
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg every 4 weeks until week 12
Study: NCT00959036
Drug: ATN-103
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg every 4 weeks until week 12
Study: NCT00959036
Drug: ATN-103
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg every 8 weeks until week 12
Study: NCT01739985
Drug: Dexamethasone + ondansetron + Placebo
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
Study: NCT01739985
Drug: Dexamethasone + ondansetron + Droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
Study: NCT01524198
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
Study: NCT02142738
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab IV solution
Study: NCT02142738
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel IV solution
Study: NCT02142738
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV solution
Study: NCT02142738
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed Lyophilized Powder for Infusion
Study: NCT02142738
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin IV solution
Study: NCT02142738
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine Lyophilized Powder for Infusion
Study: NCT00001764
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02688491
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
Study: NCT02553265
Drug: Carbidopa Low-Dose
Normalized name: ethinyl estradiol
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/day
Study: NCT01349387
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
Study: NCT02553265
Drug: Carbidopa High-Dose
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg/day
Study: NCT01529177
Drug: Metformin / clomid / hCG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
Study: NCT00356083
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02422888
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
Study: NCT02422888
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
Study: NCT00692484
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
Study: NCT00692484
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine scrub and paint. Administer topically.
Study: NCT03540225
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
Study: NCT04365309
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
Study: NCT00056264
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00382512
Drug: Raptiva (efalizumab)
Normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00019123
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02005991
Drug: PF-05212377
Normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
Study: NCT02005991
Drug: PF-05212377
Normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
Study: NCT00156247
Drug: acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
Study: NCT02109042
Drug: Blosozumab
Normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT02005991
Drug: PF-05212377
Normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
Study: NCT00404820
Drug: Alendronate 70 mg tablets
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
Study: NCT04316377
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
Study: NCT00711464
Drug: modafinil (M1, M2, M4)
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: modafinil 100, 200, and 400 mg oral dose
Study: NCT01206153
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01168973
Drug: Placebo (for Ramucirumab)
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study: NCT01168973
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study: NCT03678038
Drug: Triamcinolone (Shincort) injection to rotator interval
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: via rotator interval.
Study: NCT03678038
Drug: Triamcinolone (Shincort) injection to posterior glenuhumeral recess
Normalized name: posterior pituitary hormones
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: via posterior glenuhumeral recess
Study: NCT00382239
Drug: exenatide (LY2148568)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
Study: NCT00382239
Drug: exenatide (LY2148568)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
Study: NCT00382239
Drug: exenatide (LY2148568)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
Study: NCT00349167
Drug: PR-104
Normalized name: PR-104
DrugBank: PR-104 (DB05968)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274937
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given subcutaneously
Study: NCT00274937
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00936871
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 2400 mg single dose
Study: NCT00936871
Drug: Lersivirine (if necessary)
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 2100 mg single dose (if necessary)